gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · SRPTHealthcarePharmaceuticals

Sarepta Therapeutics,, Inc. Common Stock (SRPT)

$18.99+2.43%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$19.06▼ 22.04% in range
Nov 3, 2025Low $14.86 · High $24.45Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Sarepta Therapeutics closed at $18.99 on Nov 4, up 2.43%, 22.3% below its 52-week closing high. Volume of 1.5M shares was 0.56× its 20-day average (below normal).

Split-adjusted performance: +9.7% over one month, -17.5% over six months, -22.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $401.25M, down 34.3% from a year earlier, with a net margin of -1.2%.

Short interest was 22.3M shares at the Oct 15 settlement, down 2.0% from the prior report (22.7% of float, 7.5 days to cover).

Market cap$2.01B105.6M shares
Revenue · quarter$401.3M−34.3% YoY
Diluted EPS$-0.05−102.6% YoY
P/E · TTM—P/S 1.0×
Net margin-1.2%Gross 62.8%
Dividend yieldNone
52-week range14.86 – 24.45−22.3% from high
Volume1.5M0.56× 20-day avg
Volatility · 60d61.6%Annualised
Short % of float22.7%7.5 days to cover
Net cash-$59.1MCash $788.5M
Next earnings—Not scheduled
Split-adjusted performance
1W −1.7%1M +9.7%3M +13.2%6M −17.5%YTD −11.8%1Y −22.3%3Y −82.4%5Y −75.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum59
Revenue growth25
Net margin68
Value (low P/E)—
Size81

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short22.3M−2.0% vs prior
Days to cover7.5Settled Oct 15
% of float22.7%
Short vol. 10d50.6%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
SRPTSarepta Therapeutics,$18.99+2.43%−17.5%−34.3%−1.2%—$2.01B
HRMYHarmony Biosciences Holdings$34.42−7.04%+5.0%+30.3%28.9%11.1$2.00BCompare
TRVITrevi Therapeutics$13.99+0.90%−1.9%———$1.99BCompare
TRAXFirst Tracks Biotherapeutics$49.04+5.83%————$2.06BCompare
XERSXeris Biopharma Holdings$10.46+1.06%+64.2%+28.7%−33.8%—$1.91BCompare
SDGRSchrodinger$28.52+4.93%+119.7%+7.5%10.1%—$2.13BCompare
AGIOAgios Pharmaceuticals$31.38+0.58%+16.3%+259.3%−225.1%—$1.87BCompare
ZBIOZenas BioPharma$28.46+0.28%+36.6%—−11145.6%—$1.85BCompare
SLSSELLAS Life Sciences Group$9.14+3.04%+77.5%———$1.85BCompare

News about Sarepta Therapeutics,

All news →
Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?Zacks Investment Research · 6d ago▼ NegativeOligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta TherapeuticsGlobeNewswire Inc. · Sep 15, 2026▲ Positive

Quick answers

What does Sarepta Therapeutics do?
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases.
What is SRPT's market cap?
$2.01B, based on the Nov 4 close of $18.99.
Does Sarepta Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of SRPT is sold short?
22.3M shares, 22.7% of float, as of Oct 15, 2026.
What sector is SRPT in?
Healthcare, in the Pharmaceuticals industry.

About Sarepta Therapeutics,

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

HQ: Cambridge, MA835 employeesListed Jun 4, 1997sarepta.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology